The encapsulation of AMPs into nanoparticles (NPs) has grown into a major solution to improve stability by safeguarding proteolytic degradation, targeted drug delivery of AMPs to the site of infection, and lowering toxicity with pharmacokinetics modifications [9,10]. This evidence concerns the gene ADSL and infection.